PDE5A and angina pectoris: Albeit now widely used and specifically licensed for ED, the first clinical target of PDE5 inhibition, in pioneering researches, was angina pectoris, in view of the specific isozyme activity and expression in smooth muscle cells and platelets, where PDE5 inhibition reduces aggregation [48].